Icon introduces new drug safety reporting solution

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/spainter_vfx)
(Image: Getty/spainter_vfx)
Icon’s new drug safety reporting platform automates complex processes to ensure compliance in the ‘ever-changing’ regulatory environment, says VP.

Launched at DIA Europe last week, the solution was received positively, said Quintin Van Wyk, VP of pharmacovigilance and safety reporting at Icon.

“Sponsors are especially interested in the capability to integrate with other clinical trial applications for increased efficiency and the opportunity decrease complexity in the process,”​ he told us.

Wyk said the new cloud-based solution features automated and configurable business rules to distribute “expedited and periodic submissions to all stakeholders,”​ including investigator sites, ethics committees, institutional review boards, and competent authorities.

The system verifies and translates pharmacovigilance regulatory requirements for 80 countries into date-stamped reporting rules to track changing requirements. It also is integrated with Icon’s electronic trial master file (eTMF) for automated filing and provides an auditable distribution trail, among other features that aim to reduce time and effort for study personnel, said Wyk.

“Drug safety reporting is complex due to the evolving, ever-changing regulatory environment,”​ he explained. “Running a clinical study across multiple countries requires careful consideration of global and national country legal pharmacovigilance requirements.”

Wyk noted that it is crucial to stay current with the latest developments, adapting reporting to the required format and deadlines. 

“One country or region may have numerous regulations, directives, laws, guidance and these rules may have overlapping or contradictory requirements,” ​he added. “Appropriate interpretation of pharmacovigilance regulations requires in-depth knowledge of both global and local regulations to decipher the reporting rules and avoid over or under reporting that might affect patient safety.”

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us

Products

View more

Webinars